Company history

Alpha-9 Oncology spun out of University of British Columbia and BC Cancer in 2019. The company’s founders, François Bénard, MD, Kuo-Shyan Lin, PhD, and David Perrin, PhD, are leading researchers in the field of radiopharmaceuticals and drug design. In 2022, after the closing of its Series A and B financing, the company opened its Boston office and built research facilities in Vancouver, which are now operating at scale. The Company recently closed its Series C financing to fund multiple molecules through clinical and preclinical development. Today, Alpha-9 Oncology is advancing a broad portfolio of bespoke radiopharmaceuticals in clinical trials, bringing novel, life-improving treatments to people living with cancer.